Dublin, June 04, 2024 (GLOBE NEWSWIRE) -- The "Global Immunoglobulin Products Market 2024-2028" report has been added to ResearchAndMarkets.com's offering.
The global immunoglobulin products industry is at the brink of significant expansion, with projections indicating a growth by USD 9699.84 million over the period of 2023-2028. This growth trajectory is estimated to advance at a Compound Annual Growth Rate (CAGR) of 10.11%. An extensive analysis of market size, forecast, trends, growth drivers, and challenges underlines the robustness of this projection, highlighting the dynamism prevailing in the global immunoglobulin products market.
The market is driven by recent immunoglobulin product developments, rising prevalence of immunodeficiency disorders and autoimmune diseases, and growing geriatric population. This study identifies the advancements in biotechnology and manufacturing processes as one of the prime reasons driving the immunoglobulin products market growth during the next few years. Also, increasing adoption of subcutaneous administration and growing focus on personalized medicine will lead to sizable demand in the market.
The immunoglobulin products market is segmented as below:
By Product
- IgG
- IgA
- IgM
- IgD
- IgE
By Route Of Administration
- Intravenous (IV)
- Subcutaneous (SC)
- Intramuscular (IM)
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the immunoglobulin products market covers the following areas:
- Immunoglobulin products market sizing
- Immunoglobulin products market forecast
- Immunoglobulin products market industry analysis
The robust vendor analysis provides a detailed analysis of several leading immunoglobulin products market vendors that include ADMA Biologics Inc., Bio Products Laboratory Ltd., Biocon Ltd., CSL Ltd., GC Biopharma corp., Grifols SA, Kedrion S.p.A, LFB SA, Novartis AG, Octapharma AG, Pfizer Inc., Serum Institute of India Pvt. Ltd., Shanghai RAAS Blood Products Co. Ltd., Taibang Biological Group Co. Ltd., Taj Pharmaceuticals Ltd., and Takeda Pharmaceutical Co. Ltd.. Also, the immunoglobulin products market analysis report includes information on upcoming trends and challenges that will influence market growth.
Key Topics Covered:
1 Executive Summary
1.1 Market overview
2 Market Landscape
2.1 Market ecosystem
3 Market Sizing
3.1 Market definition
3.2 Market segment analysis
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
4 Historic Market Size
4.1 Global immunoglobulin products market 2018 - 2022
4.2 Product Segment Analysis 2018 - 2022
4.3 Route of Administration Segment Analysis 2018 - 2022
4.4 Geography Segment Analysis 2018 - 2022
4.5 Country Segment Analysis 2018 - 2022
5 Five Forces Analysis
5.1 Five forces summary
5.2 Bargaining power of buyers
5.3 Bargaining power of suppliers
5.4 Threat of new entrants
5.5 Threat of substitutes
5.6 Threat of rivalry
5.7 Market condition
6 Market Segmentation by Product
6.1 Market segments
6.2 Comparison by Product
6.3 IgG - Market size and forecast 2023-2028
6.4 IgA - Market size and forecast 2023-2028
6.5 IgM - Market size and forecast 2023-2028
6.6 IgD - Market size and forecast 2023-2028
6.7 IgE - Market size and forecast 2023-2028
6.8 Market opportunity by Product
7 Market Segmentation by Route of Administration
7.1 Market segments
7.2 Comparison by Route of Administration
7.3 Intravenous (IV) - Market size and forecast 2023-2028
7.4 Subcutaneous (SC) - Market size and forecast 2023-2028
7.5 Intramuscular (IM) - Market size and forecast 2023-2028
7.6 Market opportunity by Route of Administration
8 Customer Landscape
8.1 Customer landscape overview
9 Geographic Landscape
9.1 Geographic segmentation
9.2 Geographic comparison
9.3 North America - Market size and forecast 2023-2028
9.4 Europe - Market size and forecast 2023-2028
9.5 Asia - Market size and forecast 2023-2028
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
9.7 US - Market size and forecast 2023-2028
9.8 China - Market size and forecast 2023-2028
9.9 Germany - Market size and forecast 2023-2028
9.10 UK - Market size and forecast 2023-2028
9.11 Japan - Market size and forecast 2023-2028
9.12 Market opportunity By Geographical Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
11.1 Overview
11.2 Vendor landscape
11.3 Landscape disruption
11.4 Industry risks
12 Vendor Analysis
- ADMA Biologics Inc.
- Bio Products Laboratory Ltd.
- Biocon Ltd.
- CSL Ltd.
- GC Biopharma corp.
- Grifols SA
- Kedrion S.p.A
- LFB SA
- Novartis AG
- Octapharma AG
- Pfizer Inc.
- Serum Institute of India Pvt. Ltd.
- Shanghai RAAS Blood Products Co. Ltd.
- Taibang Biological Group Co. Ltd.
- Taj Pharmaceuticals Ltd.
- Takeda Pharmaceutical Co. Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/oydy4d
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
